Executive Summary

Citius reported no revenue and a wider net loss in Q2 FY25 as it readied LYMPHIR for launch; EPS of -$1.27 missed S&P Global consensus EPS of $0.11, while revenue matched a $0.0 consensus as the company remains pre-revenue . EPS consensus from S&P Global shown with an asterisk; see disclaimer.*
Management emphasized imminent commercialization of LYMPHIR (J-code effective April 1, 2025) and continued financing needs; cash was $26,410 at quarter-end, and the company stated it needs additional capital to support operations beyond May 2025 .
Strategic actions included amending the Eisai license to align payments with the commercialization timeline and retaining Jefferies to evaluate strategic alternatives for Citius Oncology (CTOR) .
Stock reaction: CTXR fell 11.7% the trading day after the Q2 release (5/14/25), reflecting the miss and liquidity concerns .

What Went Well and What Went Wrong

What Went Well

LYMPHIR reimbursement readiness advanced: permanent HCPCS J-code (J9161) effective April 1, 2025, which facilitates billing and payer coverage, a key launch enabler .
Launch preparations progressed: first-year launch supply produced; healthcare provider education, market access groundwork, and patient support infrastructure underway .
Clarified next steps for pipeline: preparing an FDA submission based on feedback for Mino-Lok after Phase 3 met primary endpoints, indicating a pathway toward a future NDA .

What Went Wrong

Earnings miss and continued losses: Q2 EPS -$1.27 vs S&P Global consensus $0.11*, driven by higher G&A and R&D and a year-ago benefit from selling New Jersey NOLs; no revenue yet to offset expenses .*
Liquidity risk escalated: only $26,410 cash at 3/31/25; management stated additional capital is needed to support operations beyond May 2025, implying urgency and dilution risk .
Increased LYMPHIR-related R&D costs (six-month basis) due to drug substance batch for pre-license inspection, contributing to elevated spend ahead of commercialization .

Financial Results

Metric	Q2 2024 (YoY)	Q1 2025 (QoQ)	Q2 2025 (Current)	Consensus (Q2 2025)
Revenue ($)	$0	$0	$0	$0.0*
Total Operating Expenses ($)	$10,970,201	$10,039,614	$11,260,678	—
Operating Loss ($)	$(10,970,201)	$(10,039,614)	$(11,260,678)	—
Net Loss ($)	$(8,544,154)	$(10,281,246)	$(11,511,505)	—
Diluted EPS ($)	$(1.34)	$(1.30)	$(1.27)	$0.11*

Notes:

No margins are presented as revenue was $0 in all periods.
Q2 2024 benefited from $2.39M gain on sale of NJ NOLs, boosting other income YoY .
S&P Global estimates marked with asterisk; see disclaimer.*

Operating expense detail and KPIs:

KPI / Expense	Q2 2024	Q1 2025	Q2 2025
R&D Expense ($)	$3,605,898	$2,127,038	$3,766,525
G&A Expense ($)	$4,285,911	$5,387,752	$4,792,122
Stock-based Comp – G&A ($)	$3,078,392	$2,524,824	$2,702,031
Cash & Equivalents (end of period, $)	—	$1,100,079 (12/31/24)	$26,410 (3/31/25)
Inventory (end of period, $)	—	$14,381,369	$15,339,253
Accounts Payable (end of period, $)	—	$7,364,120	$9,368,234
License Payable (end of period, $)	—	$28,400,000	$28,400,000
Weighted Avg Shares (basic/diluted)	6,362,890	7,492,460	8,581,207

Balance sheet snapshot (oldest → newest):

Metric	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025
Cash & Equivalents ($)	$3,251,880	$1,100,079	$26,410
Inventory ($)	$8,268,766	$14,381,369	$15,339,253
Total Current Liabilities ($)	$35,814,803	$44,805,958	$49,876,642
Total Equity ($)	$74,101,830	$68,919,459	$63,575,792
Common Shares Outstanding (period-end)	7,247,243	7,727,243	8,760,649

Guidance Changes

Metric	Period	Previous Guidance	Current Guidance	Change
LYMPHIR Launch Timing	FY1H25	“Launch in the first half of 2025” (FY24 update, Dec-2024)	Launch preparations ongoing; J-code effective Apr 1, 2025; first-year supply produced	Maintained; execution milestones achieved
R&D Expense Trend	FY2025	Expect R&D to decrease in FY2025 (Q1 FY25)	Expect R&D to continue decreasing in FY2025 as focus shifts to LYMPHIR commercialization	Maintained
Liquidity/Runway	Near-term	Raise additional capital to support operations (FY24)	Needs additional capital to support operations beyond May 2025	Worsened (timing more urgent)
CTOR Strategic Actions	2025	Distribute CTOR shares by end-2025 subject to conditions (FY24)	CTOR retained Jefferies to evaluate strategic alternatives	Evolving (strategic review underway)
Mino-Lok Regulatory Path	2025	Continued FDA engagement post-Phase 3	Preparing FDA submission based on agency feedback to support future NDA	Clarified next step

No quantitative revenue, margin, OpEx, or tax rate guidance was provided in Q2 materials .

Earnings Call Themes & Trends

No Q2 FY25 earnings call transcript was found in our document system or via open web search; analysis below leverages company press releases and filings. We searched for “earnings-call-transcript” for CTXR (2025-01-01 to 2025-11-20) and found none; also checked PR Newswire/company IR pages .

Topic	Previous Mentions (Q-2 & Q-1)	Current Period (Q2 FY25)	Trend
LYMPHIR launch readiness	FY24: launch in 1H25; commercial prep ongoing . Q1: progressing toward 1H25 launch .	J-code effective 4/1/25; first-year supply produced; HCP education, access, and support in place .	Execution progressing; launch infrastructure in place
Reimbursement	Q1: CMS permanent J-code secured, effective 4/1/25 .	J-code goes live in Q2 period; coding clarity for payers/providers .	Positive catalyst realized
Financing/capital	FY24: planned capital raises . Q1: raised $6.5M gross; ongoing needs .	April 2025 direct offering (~$1.735M net); company needs capital beyond May 2025 .	Urgency increased; dilution risk elevated
CTOR strategic path	FY24: CTOR distribution targeted by YE25, conditions permitting .	CTOR retained Jefferies to evaluate strategic alternatives .	Strategy under active review
Mino-Lok regulatory	FY24: continued FDA engagement post-Phase 3 .	Preparing FDA submission per feedback to support future NDA .	More concrete next step
Manufacturing/supply chain	—	First-year LYMPHIR launch supply produced; CMOs secured .	Launch readiness improved

Management Commentary

“We are actively engaged in securing the necessary financing to advance our launch strategy in the coming months, as well as exploring strategic partners for Citius Oncology.” — Leonard Mazur, Chairman & CEO .
“We are also in the process of preparing a submission to the FDA… a key step toward supporting a future New Drug Application (NDA) for our Mino-Lok program… our Phase 3 Trial… met its primary endpoints.” — Leonard Mazur .
“We… amended our license agreement with Eisai to align our payment obligations with our commercialization timeline.” — Leonard Mazur .
On reimbursement: “The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR… facilitating reimbursement.” — Leonard Mazur .

Q&A Highlights

No Q2 FY25 earnings call transcript was available; the company’s commentary is limited to the press release and filings .
As such, there were no published analyst Q&A clarifications on launch pacing, initial LYMPHIR demand, or cash runway beyond the disclosed “beyond May 2025” statement .

Estimates Context

EPS: Actual -$1.27 vs S&P Global consensus $0.11*; a significant miss driven by higher operating expenses and lack of one-time other income vs prior year .*
Revenue: Actual $0 vs S&P Global consensus $0.0*, consistent with pre-revenue status .*
We note other aggregators showed different EPS consensus for Q2 FY25; for consistency, this recap anchors on S&P Global consensus per instruction .*

Actual vs. consensus (current quarter):

Metric	Actual	Consensus
Revenue ($)	$0	$0.0*
EPS ($)	$(1.27)	$0.11*

Key Takeaways for Investors

Near-term catalyst is LYMPHIR’s commercial start with reimbursement infrastructure in place (J-code live 4/1/25); inventory build suggests readiness, but timing of initial orders remains the key swing factor for CTXR .
Liquidity is the principal risk: $26,410 cash at 3/31/25 and explicit need for additional capital beyond May 2025 point to ongoing dilution or partnering as likely funding paths .
Strategic optionality via CTOR: Jefferies-led review could lead to financing, partnerships, or structural changes; outcome may influence capital needs at the parent (CTXR) .
Pipeline clarity improved: upcoming FDA submission for Mino-Lok (post-Phase 3 success) offers a second value driver beyond LYMPHIR, though timelines are not guided .
Expense profile should moderate in FY25 per management (R&D decline as commercialization focus intensifies), aiding burn once revenue begins, but near-term losses persist absent sales .
Stock traded down 11.7% post-print, reflecting the miss vs consensus and runway concerns; upside scenario hinges on clean early launch execution and financing on acceptable terms .
Monitor: first commercial LYMPHIR sales, payer uptake, any CTOR strategic outcomes, and details of the Eisai license payment alignment to the launch timeline .

—
*Values retrieved from S&P Global.

Citius Pharmaceuticals, Inc. (CTXR)·Q2 2025 Earnings Summary